Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Biguanides + Sodium-glucose transport proteins (SGLT2) inhibitors & Type 2 diabetes (T2D)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Biguanides (primarily metformin) and Sodium-glucose transport proteins (SGLT2) inhibitors are complementary oral agents used in type 2 diabetes (T2D); their combination improves glycemic control, weight, and blood pressure while offering additional cardio‑renal benefits beyond either drug alone.
Milder et al. 2019 J Clin Med 8(1): 45
Jingfan et al. 2019 Arch Endocrinol Metab 63(5): 478-486

Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis
Milder et al. 2019 J Clin Med 8(1): 45
Meta-Analysis
Review
Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on metformin: a meta-analysis
Jingfan et al. 2019 Arch Endocrinol Metab 63(5): 478-486

7/1/2026